Triple Negative Breast Cancer By Amit Agarwal
SESSION 3 : TRIPLE NEGATIVE BREAST CANCER
Chairpersons :
R. Gopal, Manohar Chari, N. Sudhakar
Reviewer :
Amit Agarwal
1. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients
(pts) with HER2-negative Metastatic Breast Cancer (MBC) and a germline BRCA
mutation (gBRCAm)
Author: Mark E. Robson
Citation: ASCO ABSTRACT LBA4 Journal of Clinical Oncology 35, no. 15_suppl
2. Final results of a phase 2 study of Talazoparib (TALA) following platinum or multiple
cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2
mutations (ABRAZO)
Author: Nicholas C. Turner
Citation: ASCO Abstract 1007 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)
1007-1007
3. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's
choice of therapy in patients with advanced breast cancer and a germline BRCA
mutation
Author: Litton J.
Citation: SABCS Abstract GS6-07
4. Phase 3 study evaluating efficacy and safety of Veliparib (V) plus Carboplatin (Cb) or
Cb in combination with standard Neoadjuvant Chemotherapy (NAC) in patients (pts)
with early stage Triple-Negative Breast Cancer (TNBC)
Author: Charles E. Geyer
Citation: ASCO ABSTRACT 520 Journal of Clinical Oncology 35, no. 15_suppl (May
2017) 520-520